RVTY · News · 20260804N
Guidance / Outlook
REVVITY, INC. · 2026-08-04 · Importance 57 · Surprise 60 · In source text
Revvity raised its full-year 2026 revenue guidance to $2.83-$2.86 billion and pro forma adjusted EPS guidance to $5.30-$5.40. Management attributed the improved outlook to stronger diagnostics demand, increased demand for drug-development tools, and incremental AI-related work. The company also plans to reinvest part of its gains into growth initiatives, including supply chain and R&D investments.
Key facts
- Raised full-year 2026 revenue guidance to $2.83-$2.86 billion. source
- Raised full-year 2026 pro forma adjusted EPS guidance to $5.30-$5.40. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Raised full-year 2026 revenue guidance to $2.83-$2.86 billion. |
| net_income | positive | probable | — | Raised full-year 2026 pro forma adjusted EPS guidance to $5.30-$5.40. |